Literature DB >> 8256212

Reoperation for recurrent or persistent medullary thyroid cancer.

J F Moley1, S A Wells, W G Dilley, L E Tisell.   

Abstract

BACKGROUND: Initial operations for medullary thyroid cancer (MTC) frequently do not eradicate all disease, as evidenced by persistently elevated levels of stimulated plasma calcitonin.
METHODS: Thirty-two patients with MTC and elevated stimulated plasma calcitonin levels after thyroidectomy were studied between 1990 and 1993. Thirty-five repeat neck explorations and microdissections were performed. Four patients also underwent a median sternotomy and mediastinal dissection.
RESULTS: In nine patients (group 1), stimulated plasma calcitonin levels were undetectable after reoperation, whereas in 13 cases (group 2) the calcitonin levels decreased by 40% or more. In 10 cases (group 3) the CT levels did not decrease. Primary tumors that exhibited invasive features (invasion of adjacent structures or extranodal or extracapsular spread) were found more often in patients from group 3 than in patients from groups 1 or 2 (p < 0.05, Fisher's exact test).
CONCLUSIONS: Reoperation resulted in normalization of calcitonin levels in 28% of patients and a decrease in calcitonin levels by 40% or more in another 42% of patients. The data also suggest that patients whose primary MTC has invaded tissues beyond the thyroid gland or a lymph node capsule are less likely to benefit from repeat operation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8256212

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  15 in total

1.  Prognostic significance of disseminated tumor cells in the connective tissue of patients with medullary thyroid carcinoma.

Authors:  Oliver Gimm; Viola Heyn; Ulf Krause; Carsten Sekulla; Jörg Ukkat; Henning Dralle
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

2.  Long-term outcome of reoperations for medullary thyroid carcinoma.

Authors:  Elizabeth Fialkowski; Mary DeBenedetti; Jeffrey Moley
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

3.  Medullary thyroid carcinoma in Northern Ireland, 1967-1997.

Authors:  S J Dolan; C F Russell
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

4.  Improved results of cervical reoperation for medullary thyroid carcinoma.

Authors:  J F Moley; W G Dilley; M K DeBenedetti
Journal:  Ann Surg       Date:  1997-06       Impact factor: 12.969

Review 5.  Medullary thyroid carcinoma--update and present management controversies.

Authors:  Mahir Al-Rawi; Malcolm H Wheeler
Journal:  Ann R Coll Surg Engl       Date:  2006-09       Impact factor: 1.891

6.  Single center experience in primary surgery for medullary thyroid carcinoma.

Authors:  Jörg Ukkat; Oliver Gimm; Michael Brauckhoff; Udo Bilkenroth; Henning Dralle
Journal:  World J Surg       Date:  2004-11-04       Impact factor: 3.352

7.  The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.

Authors:  Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

Review 8.  Evidence-based approach to the management of sporadic medullary thyroid carcinoma.

Authors:  Jeffrey F Moley; Elizabeth A Fialkowski
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 9.  Role of surgeons in clinical trials for thyroid cancer.

Authors:  Y Nancy You; Samuel A Wells
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

10.  Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection.

Authors:  H Chen; J R Roberts; D W Ball; D W Eisele; S B Baylin; R Udelsman; G B Bulkley
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.